HemaQuest Pharmaceuticals Secures $12,000,000 Series B Financing Round

  • Feed Type
  • Date
    4/22/2010
  • Company Name
    HemaQuest Pharmaceuticals
  • Mailing Address
    1229 Madison Street Seattle, WA 98104
  • Company Description
    HemaQuest is a company developing proprietary small molecule therapeutics to treat serious blood disorders.
  • Website
    http://www.hemaquest.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $12,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The financing is intended to help advance HemaQuest’s two lead products, HQK-1001 and HQK-1004, into pre-pivotal Phase 2 clinical trials.
  • M&A Terms
  • Venture Investor
    Aberdare Ventures
  • Venture Investor
    De Novo Ventures
  • Venture Investor
    Forward Ventures
  • Venture Investor
    Lilly Ventures

By posting a comment, you agree to our terms and conditions.